Alpha Teknova Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
15.6%projected annual EPS growth
Analyst Coverage
3analysts covering
FY Revenue (est.)
$43.8Mnext fiscal year
FY EPS (est.)
-$0.33next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Total Revenue Quarterly11.1MTarget: 42000000 to 44000000
Free Cash Outflow Quarterly3.6MTarget: Less than 10000000
Gross Margin Quarterly34.2%Target: Mid-30% range
Watch Items
- Biopharma customer spending recoveryTrigger: Sustained double-digit revenue growth in Lab Essentials and Clinical SolutionsAction: Monitor quarterly segment revenue and management commentary on biotech funding environments.
- Adjusted EBITDA BreakevenTrigger: Annualized revenue run-rate of $52 million to $57 millionAction: Track quarterly annualized revenue run-rate and progress of clinical solutions pipeline commercialization.
Research as of 20 Jun 2026